Anti-Lung Cancer Compound Library

Cat. No. : CS-L075 (1665 compounds)
Library Contents: PDF | SDF

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1665 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Size (Pre-dissolved DMSO or Solid) Stock Price
30 μL/well (10 mM solution) In-stock Get quote
50 μL/well (10 mM solution) In-stock Get quote
100 μL/well (10 mM solution) In-stock Get quote
250 μL/well (10 mM solution) In-stock Get quote
Products are for research use only. Not for human use. We do not sell to patients.

Bulk Inquiry

Collapse
Your information is safe with us. * Required Fields
  Salutation:
* Country or Region:
* Applicant name:
* Organization Name:
* Email address:
* Requested quantity:
* Phone number:
  Remarks:
 
Please slide the slider!
>>
 
Name, 
Organization name, 
Email address, 
Requested quantity, 
Phone number, 

Request SDF File

x

Please enter your email address. We will send your requested SDF file to you as soon as possible.

  • Data Sheet

  • Description & Advantages

  • Composition

  • Contents

Formulation:A collection of 1665 anti-lung cancer compounds supplied as pre-dissolved Solutions or Solid
Container:96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Storage:-80°C
Shipping:Blue ice

•   A unique collection of 1665 compounds with identified and potential anti-lung cancer activity for high throughput screening (HTS) and high content screening (HCS).

•   Targets include EGFR, BRAF, ROS1,ALK,etc.

•   A useful tool for the discovery of anti-lung cancer drugs.

•   Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.

•   Structurally diverse, medicinally active, and cell permeable.

•   Detailed compound information with structure, IC50, and brief introduction.

•   Validated NMR and HPLC to ensure high purity and quality.

•   All compounds are in stock and continuously updated.

PDF
Browsing History

    Customize Your Library

    You can select:
    • Specific Compounds
    • Quantities
    • Plate map
    • Concentration
    • Format (Solid or DMSO Solution)

    Please contact us at sales@chemscene.com

    Recommend Products
    CS-L096 Cat. No. : CS-L096

    (177 compounds)

    Inactive Ingredient Library

    CS-L022P Cat. No. : CS-L022P

    (3036 compounds)

    FDA-Approved Drug Library Plus

    CS-L163 Cat. No. : CS-L163

    (317 compounds)

    FDA-Approved Traditional Chinese Medicine Active Compound Library